Abstract | BACKGROUND: METHODS: Immunohistochemistry was performed on osteosarcoma samples from patients at the time of initial biopsy, definitive surgery, and disease recurrence. The intensity and location of staining were scored. Cell-based enzyme-linked immunoadsorbent assay was performed on osteosarcoma cell lines to quantitate the level of GD2 expression. RESULTS: Forty-four osteosarcoma samples were evaluated by immunohistochemistry, including 8 samples from the initial biopsy, 28 samples from the definitive surgery, and 8 samples from the time of disease recurrence. GD2 was expressed on all 44 osteosarcoma samples. Osteosarcoma tissue obtained at the time of disease recurrence demonstrated a higher intensity of staining compared with samples obtained at initial biopsy and definitive surgery (P = .016). The majority of osteosarcoma cell lines expressed GD2 at higher levels than the neuroblastoma cell line BE(2)-C. CONCLUSIONS:
|
Authors | Michael Roth, Marissa Linkowski, John Tarim, Sajida Piperdi, Rebecca Sowers, David Geller, Jonathan Gill, Richard Gorlick |
Journal | Cancer
(Cancer)
Vol. 120
Issue 4
Pg. 548-54
(Feb 15 2014)
ISSN: 1097-0142 [Electronic] United States |
PMID | 24166473
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal
- Gangliosides
- ganglioside, GD2
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Biopsy
- Bone Neoplasms
(drug therapy, genetics, pathology, surgery)
- Gangliosides
(biosynthesis, genetics, immunology)
- Gene Expression Regulation, Neoplastic
- Humans
- Neoplasm Recurrence, Local
(genetics, pathology, surgery)
- Neuroblastoma
(genetics, pathology, surgery)
- Osteosarcoma
(drug therapy, genetics, pathology, surgery)
- Primary Cell Culture
- Radioimmunotherapy
|